Can Fite Biopharma Ltd (CANF) FinancialsCANFCan Fite Biopharma Ltd

Evaluating the bottom line, Can Fite Biopharma Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2456.79%, while the net margin is -2426.67%. These profitability ratios, combined with a Return on Equity (ROE) of -178.24%, provide a clear picture of how effectively CANF converts its operational activities into shareholder value.

In the context of the broader market, CANF competes directly with industry leaders such as ABVC and COCP. With a market capitalization of $7.28M, it holds a significant position in the sector. When comparing efficiency, CANF's gross margin of 100.00% stands against ABVC's N/A and COCP's 100.00%. Such benchmarking helps identify whether Can Fite Biopharma Ltd is trading at a premium or discount relative to its financial performance.

The company has a current ratio of 4.38, indicating strong liquidity, and a gross margin of 100% for upcoming quarters, which is exceptional. However, it also has a negative return on equity (ROE) of -134.94% for Q4 2024, reflecting significant losses.